Marijuana Industry Concerned About Trump’s Pick for Attorney General

The multibillion-dollar marijuana industry is concerned about Donald Trump’s choice for Attorney General, Senator Jeff Sessions, according to NPR. Sessions has made comments indicating he is not in favor of marijuana legalization.

As Attorney General, Sessions would oversee the Drug Enforcement Administration and federal prosecutors. In April, Sessions noted in a Senate hearing, “We need grown-ups in Washington to say marijuana is not the kind of thing that ought to be legalized, it ought not to be minimized, that it is in fact a very real danger.” He added that “good people don’t smoke marijuana.”

Full story of Jeff Sessions and the marijuana industry at drugfree.org

DEA Temporarily Bans Synthetic Drug Pink

The Drug Enforcement Administration (DEA) has temporarily banned the synthetic drug Pink under federal law, according to NBC News. The agency has received reports of at least 46 confirmed deaths associated with the drug.

The DEA has placed Pink, also called U-47700, on Schedule I of the Controlled Substances Act, alongside heroin, LSD and Ecstasy. The ban will last for 24 months, with a possible 12-month extension, before the DEA decides whether to make it permanent.

Full story of DEA banning synthetic drug pink at drugfree.org

Many Schools Try to Prevent Opioid Abuse Through Education Campaigns

Many schools around the country are trying to prevent opioid use through education campaigns. The Wall Street Journal reports that last year, CVS pharmacists made almost 3,000 presentations to school children about the dangers of misusing prescription painkillers.

Some schools are using a substance abuse prevention program aimed at students as young as fourth grade. Others are offering a texting tool that quickly connects students to a licensed therapist. The tool, called Text a Tip, hides teens’ phone numbers so they can ask questions anonymously.

Full story of preventing opioid abuse and education programs at ed.gov

Study Shows Promising Results for Injectable Treatment for Opioid Dependence

A new injectable treatment for opioid addiction showed promise in a late-stage study, according to The Wall Street Journal. The study involved weekly and monthly injections of buprenorphine for the treatment of moderate to severe opioid use disorder.

Buprenorphine is currently available as a tablet and as film that dissolves in the mouth. According to Braeburn Pharmaceuticals, which makes the new treatment, the study included 428 patients. It showed the injections were superior to the tablet treatment.

Full story of injectable treatment for opioid dependence at drugfree.org

Some People Ask Judges to Lock Them Up to Get Inpatient Opioid Addiction Treatment

Some people addicted to heroin are asking judges to lock them up so they can get access to treatment for opioid addiction, NPR reports.

In Massachusetts, some people addicted to opioids are using a law designed for family members to commit loved ones to a locked facility if they are deemed to be a danger to themselves or others because of substance use. Thirty-eight states allow civil commitment for substance abuse, the article notes.

Full story of addicts trying to get opioid addiction treatment at drugfree.org